The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I think SOG should be appointed to the BOD without delay in order to represent shareholders interests! :-) That way these financial co*ck up's should not happen again!
If any deal was being done, l don't believe a company round touch us with a barge pole whilst involved in RF funding.
Most likely a reason why we have cleared early!
Sareum have 3 advisors.
Broker 1 - Hybridan - They do our reports, broker notes etc. I think we oat them £60k a year.
Broker 2 - Peel Hunt - if we are to believe the board, PH were engaged to market Sareum to institution investors. To do that, the company needs to be stable, investable and a, safe ish pair of hands. IMO, PH will have recommended the consolidation, because over 3 billions shares in issue make you look like a penny stock. Ironically, that where Sareum find themselves again.
Nomad - Strand Hanson are the Nominated and Financial Advisors. They would have looked at this RF and advised on it but at the end of the day, the buck stops at Parker and the board. It looks like zero due diligence was done. 10 minutes on Google and lse chats boards would have told them RF were bad news.
I dont want a witch hunt but I also dont get why we give the board a free ride here. Their decisions nearly finished the company.
It's done now but we, the shareholders must never let it happen again.
Yes, the fact that the Psoriasis market is worth $60 billion annually highlights just how big this opportunity is for SDC-1801. As you say an approach to Sareum soon about licencing SDC-1801 looks a real possibility.
I did actually
Exactly and it is worth noting there were 108 licencing deals alone in Q4 in our sector, according to JP Morgan, worth a cumulative $8.2 billion in total in upfront cash and equity....
Good luck, Brighty
''We deserve to be informed by the BOD who it was who suggested RF and who knew their form''.
We certainly do fearg (and my money's on Parker and 'Real C**t' in that order, but all in my own opinion of course!) but whether we will though is a different matter!?!
Still news is due soon (hopefully good) and the sp certainly appears to be moving in the right direction (for now!).
Ignore nicely,
That's a bait post to expand the 'Seller' subject as people reply to him. Try using this one. Should have bought when you had the chance.
LOl, clueless and filtered.
Sellers seem to have offloaded to get their 10% should go back blue
Every thread has a Walter Mitty, this one has two , nicely and Gregorio.
I agree Nicely, would have saved us all the risk of death from boredom.
Nicely, why don't you keep quiet until it goes back up to 4 pound 70?
Soot on Rebster408.
Nice pertinent post to Aber
Regards
Very little difference when I was in at £4.70
Nicely - use your brain - spouting you were 100K down when we were at 10p ... and you are still 100K down at 33p .... surely not mate ... pure BS
I’ll take 7k at 33
GLA
Rebster408, spot on . That one is always the same I think probably one of the attention seekers that never actually buys stock ever.
Nicely
As you keep saying...'I might be wrong'... but with every post you seem to be outing yourself more and more...
You have an agenda and its not for the SP to rise...
Unlucky lad.. move onto something else.
If it does go red I’ll be topping up more so I don’t really need that £5 thank you
Another company exposed to the expiry of patents – and who therefore could be looking for a licencing deal for SDC1801 - is Bristol Myers Squibb. They potentially could be losing exclusivity soon of Revlimid, Eliquis and Opdivo.
• Revlimid has reported global sales of $12.1 billion and its patent expiration is said to be by 2026.
• Eliquis with reported sales of over $9 billion has a patent expiration between 2027 & 2029.
• Opdivo, with reported annual sales of over $6 billion has a patent expiration dated of 2028.
"Patent Cliffs" are becoming the big issue for the major players in our sector.
Bristol Myers Squibb could therefore be one to watch regarding a partnership for SDC1801....
Good luck, Brighty
Offering 35.1 now
Opened at 37-39p has settled at 34-35p which is still up on yesterday.
They will take my 9 grand for 34.5p a share
Cando66 .
If this finishes blue I'll send you £5 for you to donate to your fav charity
If it finishes red ,you send me a 5er for Marie curie